Simple Personalized Investing
Salix valuation
|
Use Salix Pharmaceuticals Ltd valuation together with your other stock asset holdings to enhance returns of your portfolios as well as to check it against diversification policy that fits your risk preferences. Optimize Portfolio
Salix Pharmaceuticals Ltd is at this time projected to have valuation of 3.54 B with market capitalization of 3.65 B, debt of 866.43 M, and cash on hands of 960.29 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Salix fundamentals before making equity appraisal based on the enterprise value of the company
Salix Investor InformationAbout 103.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.86. Salix Pharmaceuticals Ltd had not issued any dividends in recent years. This company had 3:2 split on July 13, 2004. Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices used in the treatment of various gastrointestinal diseases in the United States. To find out more about SALIX PHARM DEL contact Carolyn Logan at 919-862-1000 or learn more at http://www.salix.com. Salix Asset UtilizationSalix Pharmaceuticals utilizes its assets roughly 6.71 %, earning $0.07 for each dollar of assets held by the company. An increasing assets utilization denotes the company is being more effective with each dollar of assets it has. In other words assets utilization of Salix shows how effective it operates for each dollar spent on its assetsSalix Ownership Allocation (%)Salix maintains a total of 61.3 Million outstanding shares. Majority of Salix Pharmaceuticals outstanding shares are owned by other institutions. These institutional investers are referred to non-private investors that are looking to obtain positions in Salix to benefit from reduced commissions. Consequently, institutions are subject to different set of regulations than regular investors in Salix Pharmaceuticals. Please pay attention to any change in the institutional holdings of Salix Pharmaceuticals Ltd as this could imply that something significant has changed or about to change at the company. Also note that roughly three million six hundred seventy-eight thousand invesors are currently shorting Salix expressing very little confidence in its future performance.Salix Profitability AnalysisThe company reported previous year revenue of 766.91 M. Net Income was 76.73 M with profit before overhead, payroll, taxes, and interest of 610.85 M. Salix Debt AnalysisSALIX PHARM DEL currently holds about 960.29 M in cash with 315 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.66.
|
Salix Market ShareSalix Pharmaceuticals Ltd is rated third in market capitalization category among related companies. Market capitalization of Drugs - Generic industry is at this time estimated at about 23.12 Billion. Salix retains roughly 3.65 Billion in market capitalization claiming about 16% of equities under Drugs - Generic industry.Follow Salix Valuation with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Salix RevenueBased on latest financial disclosure Salix Pharmaceuticals Ltd reported 766.91 M of revenue. This is 83.41% lower than that of Healthcare sector, and 85.1% lower than that of Drugs - Generic industry, The Revenue for all stocks is 90.38% higher than the company. |
| Frequently Asked Questions Quick Product Tour Product Technology Overview Solution Methodology Plans and Pricing |
|
World Market Correlations Instant Equity Comparator Watchlist Analysis Position Suggestions Equity Alpha Analysis |
|
About Macroaxis Contact Us Product Terms Of Use Service Privacy Policy Advertising Opportunities |
-0.06% 
Equity Search
Advanced Search
Market Screener
Adviser Directory
Suggest Portfolio
Backtest Watchlist
Analyze Correlations
View Transactions
Check Volatility
Import Equities
Advice
USD
